← Back to Search

Hormone Therapy

High-Dose Megestrol for Advanced Cancers

Phase 1 & 2
Waitlist Available
Research Sponsored by St. Vincent Medical Center - Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Indicator lesions other than blastic bony metastases and pleural effusions required for breast cancer
Age: At least 18
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will study the effectiveness of high-dose megestrol in treating patients with metastatic breast cancer, endometrial cancer, or mesothelioma.

Who is the study for?
This trial is for adults with metastatic breast, endometrial cancer, or mesothelioma that can't be removed by surgery or controlled with radiation. Participants must have a life expectancy of at least 3 months and measurable cancer lesions. Women with breast cancer should have hormone-receptor-positive tumors.Check my eligibility
What is being tested?
The study is testing high doses of the hormone therapy drug megestrol to see if it can slow down or stop the growth of certain cancers by reducing hormone production. This phase I/II trial aims to determine its effectiveness in advanced cases.See study design
What are the potential side effects?
Megestrol may cause weight gain, increased appetite, fluid retention, upset stomach, and potential hormonal changes such as hot flashes or mood swings.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast cancer has spread, but not to my bones or causing fluid around my lungs.
Select...
I am 18 years old or older.
Select...
My cancer is positive for estrogen and/or progesterone receptors.
Select...
My cancer cannot be cured or controlled long-term with surgery or radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

St. Vincent Medical Center - Los AngelesLead Sponsor
3 Previous Clinical Trials
40 Total Patients Enrolled
Charles L. Wiseman, MD, FACPStudy Chair
4 Previous Clinical Trials
64 Total Patients Enrolled

Media Library

Megestrol (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00002465 — Phase 1 & 2
Endometrial Cancer Research Study Groups:
Endometrial Cancer Clinical Trial 2023: Megestrol Highlights & Side Effects. Trial Name: NCT00002465 — Phase 1 & 2
Megestrol (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002465 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the research team currently recruiting participants?

"The listing on clinicaltrials.gov expresses that this investigation is no longer enrolling patients, having first been posted in December 1987 and last amended in November 2013. That being said, there are a substantial number of other studies actively looking for volunteers at present.; 2964 to be exact."

Answered by AI

Who else is applying?

What site did they apply to?
St. Vincent Medical Center - Los Angeles
What portion of applicants met pre-screening criteria?
Met criteria
~9 spots leftby Mar 2025